BioNTech

News

Blow to Moderna as EU nixes mRNA vaccine patent

The European Patent Office has said it has invalidated a patent held by Moderna on mRNA-based COVID-19 vaccines, the latest development in an increasingly acrimonious disp

News

BioNTech flashes the cash, adding tumour drug in $1bn deal

Fresh from slashing its predictions for COVID-19 vaccine sales this year, mRNA specialist BioNTech has used some of its extensive cash reserves to bolster its pipeline in

Sales & Marketing

The rise and fall of the pandemic overachievers

Ben Hargreaves examines how Pfizer, BioNTech, and Moderna are preparing for a future without COVID-19 revenue

News

COVID, flu combo jab from Pfizer/BioNTech heads for phase 3

A combination COVID-19 and influenza vaccine being developed by Pfizer and BioNTech has generated immune responses against the viruses in a phase 1/2 trial, setting up a p

News

ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours?

CAR-T therapies have transformed the treatment of some haematological cancers, but haven’t made much headway for solid tumours – although BioNTech thinks it may have the k

News

CureVac claims advantage in BioNTech patent dispute

A court in Germany has suspended a trial discussing litigation brought against BioNTech and Pfizer by CureVac alleging patent infringement in connection with their mRNA-ba

Blow to Moderna as EU nixes mRNA vaccine patent

BioNTech flashes the cash, adding tumour drug in $1bn deal

The rise and fall of the pandemic overachievers

COVID, flu combo jab from Pfizer/BioNTech heads for phase 3

ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours?

CureVac claims advantage in BioNTech patent dispute

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

BioNTech

Editor's Picks